Since November, 28 analysts see $ -0.28 EPS for Cellect Biotechnology Ltd. (APOP)

The quarterly earnings of Celcet Biotechnology Ltd. (NASDAQ: APOP) will be published on November 28, as reported by Faxor. Last year's earnings per share were -0.39, while analysts expect a change of 28.21% versus current -0.28 earnings per share. Wall Street forecasts a 7.69% growth in EPS, despite the fact that Cellect Biotechnology Ltd.'s most recent quarter was $ 0.26. APOP reached $ 4.55 during the last trading session after the change of $ 0.02. Cellect Biotechnology Ltd. has a volume of 109 shares. Starting November 13, 2017, APOP declined by 41.02% and is down. Shares of the S & P500 surpassed 56.64%.

Cellect Biotechnology Ltd., a biotechnology company, focuses on developing technologies for the functional selection of stem cells in regenerative medicine and stem cell therapies in Israel. The company is valued at $ 29.62 million. Develops the Apotainer Selection Kit, a Shell Stem Cell Selection Kit, based on Cellect Powered Cellular Technology Platform for haematopoietic stem cell transplantation for patients suffering from hematologic malignancies. He subsequently reported negative earnings.

More news The latest information The latest technology Chinese celebrities news were released by: Seekingalpha.com, which launched on October 22, 2018 "40 stocks that moves in the Wednesday session of the Wednesday ", the next" Seekingalpha.com "is" Cellect Bio Up to 9% before ApoGraft Presentation "on November 1, 2018. Streetinsider.com has an article entitled" Orthopedic Apoptosis Biotechnology Cells (APOP) using ApoGraft on Enriched Strain … ".